Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00heartenhttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pnghearten2018-07-24 09:11:452020-07-28 11:24:58Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
Trianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
Two research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00heartenhttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pnghearten2016-11-23 09:10:362020-07-28 11:25:19BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer
Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
/in Press ReleasesEnthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
Enthera and Trianni Announce Licensing Agreement
/in Press ReleasesTrianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer
/in Press ReleasesTwo research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners.